Bizengri Side Effects

Generic name: zenocutuzumab

Medically reviewed by Drugs.com. Last updated on Apr 10, 2025.

Note: This document provides detailed information about Bizengri Side Effects associated with zenocutuzumab. Some dosage forms listed on this page may not apply specifically to the brand name Bizengri.

Applies to zenocutuzumab: intravenous solution.

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Some serious side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

Call your doctor at once if you have:

• feeling light-headed, loss of consciousness;

• new or worsening breathing problems--trouble breathing, shortness of breath, cough, fever; or

• new or worsening heart problems--swelling, rapid weight gain, feeling short of breath, cough, tiredness, irregular heartbeats.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

• nausea, vomiting, diarrhea, constipation, stomach pain;

• swelling in your breast, face, ankles or legs;

• tiredness, muscle or bone pain;

• skin rash;

• abnormal liver function tests;

• low red blood cell and platelet counts;

• low sodium, magnesium, and phosphate levels; or

• abnormal blood clotting tests.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

See also:

For healthcare professionals

Applies to zenocutuzumab: intravenous solution.

General adverse events

The most common adverse events were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions, dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities were increased gamma-glutamyl transpeptidase (GGT), decreased hemoglobin, decreased sodium, decreased platelets, increased AST, increased ALT, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time (aPTT) and increased bilirubin.^[Ref]

Hematologic

• Very common (10% or more): Decreased hemoglobin (35%), decreased platelets (26%), hemorrhage (up to 23%), decreased leukocytes (21%)
• Uncommon (0.1% to 1%): Myelodysplastic syndrome^[Ref]

Immunologic

• Very common (10% or more): Infusion-related reactions (up to 13%)^[Ref]

Infusion-related reactions (IRR) includes chills, IRR, nausea, cough, diarrhea, back pain, body temperature increased, dyspnea, face edema, fatigue, non-cardiac chest pain, oropharyngeal discomfort, paresthesia, pyrexia, and vomiting.^[Ref]

Musculoskeletal

• Very common (10% or more): Musculoskeletal pain (up to 28%)
• Common (1% to 10%): Traumatic fracture^[Ref]

Metabolic

• Very common (10% or more): Decreased magnesium (up to 28%), increased alkaline phosphatase (up to 31%), decreased sodium (up to 28%), decreased phosphate (26%), decreased potassium (up to 26%), decreased appetite (up to 11%)^[Ref]

Psychiatric

• Very common (10% or more): Anxiety (10%)
• Common (1% to 10%): Agitation^[Ref]

Oncologic

• Uncommon (0.1% to 1%): Tumor pain^[Ref]

Respiratory

• Very common (10% or more): Dyspnea (18%), cough (15%)
• Common (1% to 10%): Interstitial lung disease/pneumonitis, respiratory failure
• Uncommon (0.1% to 1%): Upper respiratory infection, pneumonia^[Ref]

Other

• Very common (10% or more): Fatigue (up to 21%), COVID-19 (up to 18%), edema (up to 13%), pyrexia (up to 10%)
• Uncommon (0.1% to 1%): Urinary tract infection, viral infection, sepsis, cellulitis, acute cholecystitis, lymphadenitis, staphylococcal infection^[Ref]

Renal

• Common (1% to 10%): Increased creatinine
• Uncommon (0.1% to 1%): Acute kidney injury^[Ref]

Cardiovascular

• Common (1% to 10%): Cardiac failure, Grade 2 LVEF
• Uncommon (0.1% to 1%): Tachycardia, pericardial effusion, cardiovascular fatal event, bradycardia, carotid artery stenosis^[Ref]

Dermatologic

• Very common (10% or more): Rash (14%), dry skin (10%)^[Ref]

Gastrointestinal

• Very common (10% or more): Diarrhea (up to 36%), nausea (up to 23%), vomiting (up to 23%), abdominal pain (18%), constipation (15%), abdominal distension (13%), stomatitis (up to 10%)
• Uncommon (0.1% to 1%): Ascites, dysphagia, ileus, gastric obstruction^[Ref]

Further information

Bizengri side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer